Compare DECK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | NBIX |
|---|---|---|
| Founded | 1973 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 13.2B |
| IPO Year | 1996 | 1996 |
| Metric | DECK | NBIX |
|---|---|---|
| Price | $101.64 | $179.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 22 |
| Target Price | $122.45 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.90 | ★ 41.95 |
| EPS | ★ 7.02 | 1.91 |
| Revenue | ★ $5,472,296,000.00 | $161,626,000.00 |
| Revenue This Year | $11.16 | $24.73 |
| Revenue Next Year | $6.96 | $13.14 |
| P/E Ratio | ★ $13.92 | $92.36 |
| Revenue Growth | 9.76 | ★ 977.51 |
| 52 Week Low | $78.91 | $122.14 |
| 52 Week High | $125.45 | $181.18 |
| Indicator | DECK | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 64.49 |
| Support Level | $97.84 | $153.96 |
| Resistance Level | $105.45 | $181.18 |
| Average True Range (ATR) | 3.53 | 4.76 |
| MACD | -0.65 | -0.14 |
| Stochastic Oscillator | 53.50 | 96.30 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.